KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Generating the Evidence to Support Stereotactic Radiation Therapy Evolution: Challenges and a Roadmap for Progress. PMID 41651386 · Int J Radiat Oncol Biol Phys · 2026-May-01 The article is a review/commentary on the state of phase III trials in radiation oncology, not an original result report of a randomized trial with a drug intervention and a time-to-event endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial. PMID 41262042 · Haematologica · 2026-May-01 The record is a randomized, drug-intervention oncology trial with primary time-to-event (PFS, OS) results. However, the provided metadata (title, abstract, publication types, mesh terms) does not explicitly state the trial phase as Phase III, IIIb, or Phase II/III. The criteria require this phase to be explicitly established for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial. PMID 40714135 · Int J Radiat Oncol Biol Phys · 2026-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dosimetric Comparison of Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Post Hoc Analysis of a Phase 3 Trial. PMID 40482729 · Int J Radiat Oncol Biol Phys · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia. PMID 40277212 · Eur J Cancer Prev · 2026-May-01 The record describes a prospective, likely non-randomized comparative study of adjuvant HPV vaccination after conization for cervical dysplasia. While it is oncology-related, human, includes a drug intervention (vaccine), and reports time-to-event outcomes with hazard ratios, it does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial. The study design appears observational (counseled on vaccination, not randomly assigned), and the primary outcome is recurrence of HPV-related lesions/dysplasia, which is a precursor condition rather than a standard oncologic efficacy endpoint. The abstract explicitly notes that ongoing randomized trials are needed for more robust evidence, confirming this is not a definitive trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. PMID 42371751 · Curr Med Res Opin · 2026-May The record is an exploratory comparative efficacy analysis (matching-adjusted indirect comparison) synthesizing data from two existing trials (RATIONALE-305 and DisTinGuish). While it reports on randomized Phase III trials and includes a time-to-event endpoint (PFS), it is not itself a primary or original formal-result report of a single Phase III trial; it is a secondary analysis. The deterministic review correctly flagged unclear phase evidence, but the primary exclusion is the report type.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Proton Beam Therapy in Prostate Cancer: Clinical Evidence, Controversies and Future Directions. PMID 42265951 · Arch Esp Urol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial. PMID 42201929 · PLoS Med · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa. PMID 42161369 · Int J Urol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study. PMID 42157574 · Eur J Neurol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies. PMID 42152504 · ACR Open Rheumatol · 2026-May The study is not oncology-related (psoriatic arthritis) and does not have a time-to-event efficacy endpoint (OS, PFS, etc.) as required.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials. PMID 42140261 · J Natl Compr Canc Netw · 2026-May The record is a meta-analysis of RCTs for cancer-related fatigue, not an original trial report. While it discusses phase III data and drug interventions, its primary endpoint is a patient-reported fatigue score (FACIT-F), not a time-to-event efficacy endpoint (e.g., OS, PFS).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The ILEOSTIM trial: A multicentre randomised controlled trial evaluating the impact of efferent loop stimulation prior to ileostomy reversal on postoperative ileus. PMID 42092745 · Colorectal Dis · 2026-May The record is excluded because it lacks a drug-containing intervention (it evaluates a procedural intervention: efferent loop stimulation) and does not have a time-to-event efficacy endpoint (the primary endpoint is the incidence of postoperative ileus, a binary outcome, not OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. PMID 42080361 · Future Oncol · 2026-May This is an original, pre-specified exploratory analysis from a Phase III randomized trial (NAPOLI 3) in an oncology setting (metastatic pancreatic ductal adenocarcinoma) with a drug-containing intervention (NALIRIFOX vs. gemcitabine plus nab-paclitaxel). However, the report's primary focus and results are exclusively on safety/toxicity outcomes (treatment-emergent adverse events) stratified by a biomarker (UGT1A1*28 genotype). It does not report any formal time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curves) as required for inclusion in this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers. PMID 42053460 · J Clin Pharmacol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of the Oncologist's Recommendation on Exercise Levels and Quality of Life in Patients With Lung Cancer: The ORE Randomized Controlled Trial. PMID 42036773 · Cancer Med · 2026-May This is an oncology randomized trial in humans, but it does not meet the core eligibility criteria. It is not a drug-containing intervention trial (the intervention is an exercise recommendation/guidebook). Furthermore, it does not have a time-to-event efficacy endpoint such as OS, PFS, or DFS; its primary endpoints are changes in exercise behavior and quality-of-life scores.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol for a pilot-randomized trial in newly diagnosed glioblastoma: standard care with or without daily intranasal perillyl alcohol. PMID 42015796 · Future Oncol · 2026-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial. PMID 41997828 · Clin Lung Cancer · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis. PMID 41996022 · Target Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial. PMID 41985366 · Thromb Res · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Managing myelofibrosis in the frailty era: the expanding role of JAK inhibitors. PMID 41982071 · Leuk Lymphoma · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children's Oncology Group randomized trial ACCL1033. PMID 41975001 · Leukemia · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Drainage of Pleural Effusion in the Intensive Care Unit (DOPE-ICU) Feasibility Trial-Protocol and Statistical Analysis Plan. PMID 41952333 · Acta Anaesthesiol Scand · 2026-May The record describes a feasibility protocol for a randomized trial in ICU patients with pleural effusion. It is not an oncology study, does not involve a drug intervention (it is a procedural intervention), is not a Phase II/III or Phase III/IIIb trial (it's a feasibility study), and lacks a primary time-to-event efficacy endpoint. The report is a protocol without results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial. PMID 41910921 · Breast Cancer · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial. PMID 41905323 · Gynecol Oncol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells. PMID 41882992 · Br J Haematol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial. PMID 41876649 · Nat Med · 2026-May The study is a randomized, multicenter, oncology trial in humans, reporting original results. However, it is excluded because it does not involve a drug-containing intervention (it evaluates an AI diagnostic tool) and does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary outcomes are process metrics (time to CT, time to diagnosis) and not survival or time-to-event endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial. PMID 41871353 · Ann Intern Med · 2026-May The trial is a randomized Phase III study in human oncology (breast cancer) with a drug intervention (pegfilgrastim). However, the primary and secondary endpoints are not time-to-event efficacy measures (OS, PFS, DFS, etc.). The primary endpoint is the AUC of a daily pain score, and secondary endpoints are incidence rates of pain, neutropenia, and febrile neutropenia. No Kaplan-Meier, hazard ratio, or other time-to-event analysis is reported. Therefore, it does not meet the time-to-event criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Music Intervention on Pain, Anxiety, and Vital Signs in Radiotherapy Patients: A Randomized Controlled Trial Based on the Roy Adaptation Model. PMID 41871042 · Clin Nurs Res · 2026-May The study is excluded because it is a non-drug, non-oncology-directed Phase III trial with non-time-to-event endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The whole-course of supervised home-based multi-modal prehabilitation to improve clinical outcome in patients undergoing neoadjuvant chemotherapy prior to gastrectomy: a single-center randomized controlled trial. PMID 41870736 · Gastric Cancer · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study. PMID 41870735 · Gastric Cancer · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Assessing and Listening to Individual Goals and Needs (ALIGN) versus enhanced usual care for hospitalized older patients with cancer discharged to skilled nursing facilities: Protocol for a pilot randomized controlled trial. PMID 41861729 · J Geriatr Oncol · 2026-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comment on low-dose fractionated radiotherapy during induction chemotherapy for node-positive locoregionally advanced nasopharyngeal carcinoma: a randomized phase II trial. PMID 41861716 · Oral Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cocoa flavanol supplementation and prevention of cardiovascular disease: a novel analysis of the COSMOS randomized trial using "win ratio". PMID 41849087 · Eur J Epidemiol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Motivational interviewing for health behavior change among young adults in Canada: Findings from the MOTIVATE pilot randomized controlled trial. PMID 41846588 · Prev Med Rep · 2026-May 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Healthcare Systems Data (HSD) to Improve the Efficiency of Clinical Trials Within the UK: A Prospectively Planned Comparison of HSD and Trial-Reported Outcomes Within the Add-Aspirin Cancer Clinical Trial. PMID 41844499 · Clin Oncol (R Coll Radiol) · 2026-May This is a methodological study within an ongoing trial, not an original report of the trial's efficacy results. The abstract does not present any time-to-event efficacy data (e.g., hazard ratios, survival curves) and the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Restoring circadian homeostasis is associated with immune-metabolic recovery and medium-term oncologic outcomes after rectal cancer surgery: a prospective randomized trial. PMID 41840084 · Surg Endosc · 2026-May The study fails to meet two required criteria: it is not a Phase III/IIIb or Phase II/III trial, and it lacks a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1. PMID 41830668 · Lung Cancer · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Laparoscopic versus open hemihepatectomy: does side matter? A post-hoc analysis of the ORANGE II PLUS randomized controlled trial. PMID 41803352 · Surg Endosc · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Study protocol for weSurvive: A feasibility trial of a digital health intervention to improve quality of life and health behaviors of Appalachian cancer survivors. PMID 41802648 · Contemp Clin Trials · 2026-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial. PMID 41793820 · Lung Cancer · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Perioperative multimodal behavioral optimization improves recovery and long-term outcomes after curative gastrectomy: a randomized controlled trial. PMID 41787085 · Surg Endosc · 2026-May The trial is a randomized, oncology study with primary time-to-event efficacy endpoints (DFS, OS) and an original result. However, the intervention is non-drug-only (perioperative psychosocial program: CBT, resilience training, sleep hygiene), which does not meet the 'drug-containing intervention' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)' by R. Contieri et al. PMID 41781283 · Ann Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized clinical trial protocol: Acceptability and feasibility of combination treatment for cervical precancer among South African women living with HIV (ACT 2). PMID 41780745 · Contemp Clin Trials · 2026-May 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Cold snare polypectomy for 10-19 mm colorectal adenomas in familial adenomatous polyposis: a prospective randomized controlled trial. PMID 41736450 · Scand J Gastroenterol · 2026-May The study is a randomized controlled trial in human oncology but does not meet key eligibility criteria: the primary endpoint is a binary outcome (R0 resection), not a time-to-event endpoint, and the intervention is a procedural technique, not a drug-containing therapy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009. PMID 41733132 · Br J Haematol · 2026-May The record describes a secondary safety/infection analysis from a randomized Phase III oncology trial, not a primary or key secondary time-to-event efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT. PMID 41732215 · Clin Transl Radiat Oncol · 2026-May The record describes an ongoing phase III randomized trial of prostate and pelvic nodal SBRT (radiotherapy) versus prostate SBRT (radiotherapy). It is an oncology, human, randomized, phase III trial. However, it is excluded because: 1) It is a non-drug-only intervention (radiotherapy alone), 2) The abstract does not report any primary or secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS, HR, Kaplan-Meier curves) - it only states the trial's aim to 'determine whether...SBRT can improve outcomes', and 3) It is a protocol/abstract for a planned or ongoing trial without reported results (ClinicalTrials.gov registration is noted, but no results are provided). The deterministic review's assessment of 'no_time_to_event_signal' is correct.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiofrequency Ablation for Early Stage Breast Cancer as a Potential Alternative to Partial Mastectomy: 5-Year Results from the Multiple-Center, Single-Arm, Phase 3 RAFAELO Study (NCCH1409). PMID 41708933 · Ann Surg Oncol · 2026-May Study is a single-arm Phase III trial of radiofrequency ablation (non-drug intervention) for early breast cancer. It reports a time-to-event efficacy endpoint (5-year IBTRFS rate) but lacks a drug-containing intervention and is not randomized.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prospective Phase 2 Trial: Long-term results of a salvage brachytherapy combined with interstitial hyperthermia as Re-Irradiation for locally recurrent prostate Carcinoma. PMID 41702454 · Radiother Oncol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Normal tissue complication probability models for gastrointestinal toxicity after adjuvant (chemo)radiotherapy for cervical cancer in the PARCER trial. PMID 41698508 · Radiother Oncol · 2026-May This is an original secondary analysis from a Phase III randomized trial (PARCER), but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) with KM survival curves or HR. The study focuses on developing normal tissue complication probability (NTCP) models for gastrointestinal toxicity outcomes, which are safety/toxicity endpoints, not efficacy endpoints for a drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -